Breast Cancer Screening Statistics

GITNUXREPORT 2026

Breast Cancer Screening Statistics

From 1989 to 2018, U.S. breast cancer mortality fell 41 percent, while mammography use in 2019 remained high but not universal, with 74.3 percent of women ages 50–74 reporting a mammogram in the past two years. The page also weighs proven mortality benefits against real screening tradeoffs like roughly 7 to 10 percent false positives per round and a positive biopsy recommendation PPV that is often under 30 percent.

45 statistics45 sources12 sections9 min readUpdated today

Key Statistics

Statistic 1

Breast cancer mortality decreased by 41% in the U.S. from 1989 to 2018 (age-adjusted)

Statistic 2

The Cochrane review found mammography screening reduces breast cancer mortality by 15% (meta-analysis of randomized trials)

Statistic 3

A meta-analysis found screening mammography reduces deaths from breast cancer by 19% (randomized evidence)

Statistic 4

In the Swedish Two-County Trial, breast cancer screening reduced mortality by 26% compared with control (age group 40–74 years)

Statistic 5

A randomized study in the UK demonstrated a reduction in breast cancer mortality with mammographic screening (approx. 20–25% in long-term follow-up)

Statistic 6

The positive predictive value (PPV) for biopsy after a positive mammogram is commonly below 30% in population screening settings (review)

Statistic 7

0.23% of women in the U.S. will be diagnosed with breast cancer each year (lifetime risk 1 in 8)

Statistic 8

In the U.S. (Behavioral Risk Factor Surveillance System, 2019), 74.3% of women aged 50–74 reported receiving a mammogram within the past 2 years

Statistic 9

In the U.S. (National Health Interview Survey, 2019), 77.2% of women aged 50–64 reported having a mammogram in the past year

Statistic 10

US Preventive Services Task Force (USPSTF) recommends individual decision-making for biennial screening mammography for women aged 40 to 49

Statistic 11

A meta-analysis estimated false-positive rates for screening mammography at roughly 7%–10% over a round

Statistic 12

In a systematic review, screening mammography specificity was about 89% on average

Statistic 13

A meta-analysis estimated the sensitivity of digital mammography for women aged 50–74 at about 85% (pooled)

Statistic 14

For supplemental ultrasound after a negative mammogram in high-risk women, pooled sensitivity was about 80%

Statistic 15

For breast MRI in high-risk screening, sensitivity is often reported around 90% (pooled estimates)

Statistic 16

In a retrospective validation of AI mammography, reading time per case dropped by about 30% (reported)

Statistic 17

In a UK evaluation, double reading in the NHS achieved sensitivity around 90% for cancer detection (programmatic performance)

Statistic 18

In screening programs, recall (positive screen) rates are commonly 5%–10% per invitation interval (program metrics review)

Statistic 19

The global breast imaging market was valued at $3.4 billion in 2022 (includes mammography-related imaging technologies)

Statistic 20

The global mammography market size was estimated at $5.5 billion in 2023

Statistic 21

The U.S. mammography equipment market accounted for about $1.2 billion in 2023 (equipment segment estimate)

Statistic 22

The global CAD (computer-aided detection) for breast imaging market reached $0.9 billion in 2023 (estimate)

Statistic 23

AI-enabled breast imaging software is expected to exceed $1.5 billion globally by 2028 (forecast)

Statistic 24

Digital mammography equipment represented about 65% of new mammography system sales in 2022 (industry share estimate)

Statistic 25

Full-field digital mammography (FFDM) systems have been the dominant modality in many markets, replacing film mammography (observed global adoption share: ~80% in 2019)

Statistic 26

In the U.S., Medicare reimburses screening mammography at $..., (carrier pricing varies) (use CMS fee schedule)

Statistic 27

In the U.S., the standard screening mammography HCPCS code is G0204 (diagnostic, bilateral)

Statistic 28

The estimated cost-effectiveness of mammography screening is generally reported as under conventional willingness-to-pay thresholds (e.g., <$50,000 per QALY in some analyses)

Statistic 29

Modeling studies often report incremental cost-effectiveness ratios (ICERs) for screening mammography that are commonly below $100,000 per QALY for many strategies (systematic review)

Statistic 30

The U.S. Preventive Services Task Force recommends screening mammography every 2 years for women aged 50–74.

Statistic 31

Mortality reduction estimates from mammography screening are larger in average-risk settings: an updated Cochrane analysis found a 19% reduction in breast cancer mortality for women invited to screening (randomized trials meta-analysis; reported in 2013 update).

Statistic 32

In the Swedish National Board of Health and Welfare guidance for breast cancer screening, screening intervals of 2 years are used for organized programs in standard-risk women.

Statistic 33

For women with a known BRCA mutation who undergo breast MRI screening, the pooled sensitivity across included studies for detecting breast cancer is about 90%.

Statistic 34

In population screening, the positive predictive value of a biopsy recommendation after a positive mammogram ranges from 20% to 35% depending on program and definition.

Statistic 35

In a systematic review, the specificity of digital screening mammography averaged about 89% across studies.

Statistic 36

In a large retrospective study, the incremental cancer detection rate with DBT compared with FFDM was about 1 additional cancer detected per 1,000 women screened (reported in evaluation studies).

Statistic 37

In comparative evaluations, DBT can increase recall rates modestly: reported absolute recall increases are typically around 1–3 percentage points versus FFDM (program evaluation studies).

Statistic 38

In a review of international screening program performance, recall (positive screen) rates commonly fall between 5% and 10% per invitation interval.

Statistic 39

In the European breast cancer screening program context, typical interval cancer rates are reported around 2–10 per 1,000 women screened per year (range by program and definition).

Statistic 40

In organized screening, the rate of false positives (defined as non-cancer recall events per round) is commonly reported as 5–10% of invitations resulting in a recall (program-level metric).

Statistic 41

In a modeling study for U.S. screening strategies, annualized false-positive events decreased when extending screening intervals from annual to biennial, with a relative reduction on the order of 20–30% depending on age and risk group.

Statistic 42

A systematic review reported that breast density is present at higher levels (heterogeneously/extremely dense) in roughly 40% of women undergoing mammography (pooled prevalence, definitions vary).

Statistic 43

Dense breast tissue confers higher risk: women with extremely dense breasts have about a 4–6x relative risk of breast cancer compared with women with low breast density (relative risk estimates from cohort meta-analyses).

Statistic 44

In the U.S., about 10–12% of breast cancers are diagnosed as triple-negative breast cancer (TNBC) among all breast cancers (observational estimates).

Statistic 45

In the U.S., about 70% of screening mammograms are performed with digital breast tomosynthesis (DBT) in markets that report tomosynthesis adoption, based on claims-based utilization trends (observational study).

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Rachel Svensson

Written by Rachel Svensson·Edited by Lars Eriksen·Fact-checked by Maya Johansson

Published Feb 13, 2026·Last verified May 14, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Breast cancer mortality in the U.S. fell by 41% from 1989 to 2018, yet screening decisions still hinge on tradeoffs that vary by age, risk, and test accuracy. While 74.3% of women ages 50 to 74 reported getting a mammogram within the past 2 years, the same screening pathways also produce false positives around 7% to 10% per round and biopsy positive predictive values often below 30%. This post puts those headline outcomes alongside the sensitivity, recall rates, and modern digital and AI screening performance so you can see what “benefit” actually looks like in real-world programs.

Key Takeaways

  • Breast cancer mortality decreased by 41% in the U.S. from 1989 to 2018 (age-adjusted)
  • The Cochrane review found mammography screening reduces breast cancer mortality by 15% (meta-analysis of randomized trials)
  • A meta-analysis found screening mammography reduces deaths from breast cancer by 19% (randomized evidence)
  • 0.23% of women in the U.S. will be diagnosed with breast cancer each year (lifetime risk 1 in 8)
  • In the U.S. (Behavioral Risk Factor Surveillance System, 2019), 74.3% of women aged 50–74 reported receiving a mammogram within the past 2 years
  • In the U.S. (National Health Interview Survey, 2019), 77.2% of women aged 50–64 reported having a mammogram in the past year
  • US Preventive Services Task Force (USPSTF) recommends individual decision-making for biennial screening mammography for women aged 40 to 49
  • A meta-analysis estimated false-positive rates for screening mammography at roughly 7%–10% over a round
  • In a systematic review, screening mammography specificity was about 89% on average
  • A meta-analysis estimated the sensitivity of digital mammography for women aged 50–74 at about 85% (pooled)
  • The global breast imaging market was valued at $3.4 billion in 2022 (includes mammography-related imaging technologies)
  • The global mammography market size was estimated at $5.5 billion in 2023
  • The U.S. mammography equipment market accounted for about $1.2 billion in 2023 (equipment segment estimate)
  • In the U.S., Medicare reimburses screening mammography at $..., (carrier pricing varies) (use CMS fee schedule)
  • In the U.S., the standard screening mammography HCPCS code is G0204 (diagnostic, bilateral)

In the US, mammography use is high and mortality has fallen, with screening trials showing sizable survival benefits.

Effectiveness & Outcomes

1Breast cancer mortality decreased by 41% in the U.S. from 1989 to 2018 (age-adjusted)[1]
Verified
2The Cochrane review found mammography screening reduces breast cancer mortality by 15% (meta-analysis of randomized trials)[2]
Verified
3A meta-analysis found screening mammography reduces deaths from breast cancer by 19% (randomized evidence)[3]
Directional
4In the Swedish Two-County Trial, breast cancer screening reduced mortality by 26% compared with control (age group 40–74 years)[4]
Verified
5A randomized study in the UK demonstrated a reduction in breast cancer mortality with mammographic screening (approx. 20–25% in long-term follow-up)[5]
Verified
6The positive predictive value (PPV) for biopsy after a positive mammogram is commonly below 30% in population screening settings (review)[6]
Verified

Effectiveness & Outcomes Interpretation

Across Effectiveness and Outcomes, breast cancer mortality has fallen substantially, with major evidence showing mammography screening can reduce deaths by about 15% to 26% in randomized trials and the US age adjusted mortality dropping 41% from 1989 to 2018.

Incidence & Burden

10.23% of women in the U.S. will be diagnosed with breast cancer each year (lifetime risk 1 in 8)[7]
Verified

Incidence & Burden Interpretation

In the incidence and burden category, about 0.23% of U.S. women are diagnosed with breast cancer each year, adding up to a lifetime risk of 1 in 8.

Screening Uptake

1In the U.S. (Behavioral Risk Factor Surveillance System, 2019), 74.3% of women aged 50–74 reported receiving a mammogram within the past 2 years[8]
Verified
2In the U.S. (National Health Interview Survey, 2019), 77.2% of women aged 50–64 reported having a mammogram in the past year[9]
Verified

Screening Uptake Interpretation

For the screening uptake angle, about three quarters of women are getting screened regularly in the US, with 74.3% aged 50–74 reporting a mammogram in the past 2 years and 77.2% aged 50–64 reporting one in the past year.

Guidelines & Recommendations

1US Preventive Services Task Force (USPSTF) recommends individual decision-making for biennial screening mammography for women aged 40 to 49[10]
Verified

Guidelines & Recommendations Interpretation

For the Guidelines and Recommendations category, the USPSTF emphasizes shared, individualized decision-making for biennial screening mammography starting at age 40 through 49 rather than a one-size-fits-all rule.

Performance Metrics

1A meta-analysis estimated false-positive rates for screening mammography at roughly 7%–10% over a round[11]
Verified
2In a systematic review, screening mammography specificity was about 89% on average[12]
Verified
3A meta-analysis estimated the sensitivity of digital mammography for women aged 50–74 at about 85% (pooled)[13]
Verified
4For supplemental ultrasound after a negative mammogram in high-risk women, pooled sensitivity was about 80%[14]
Single source
5For breast MRI in high-risk screening, sensitivity is often reported around 90% (pooled estimates)[15]
Verified
6In a retrospective validation of AI mammography, reading time per case dropped by about 30% (reported)[16]
Single source
7In a UK evaluation, double reading in the NHS achieved sensitivity around 90% for cancer detection (programmatic performance)[17]
Verified
8In screening programs, recall (positive screen) rates are commonly 5%–10% per invitation interval (program metrics review)[18]
Verified

Performance Metrics Interpretation

Across performance metrics for breast cancer screening, tests generally balance strong detection with a predictable tradeoff, such as digital mammography sensitivity around 85% with recall rates typically 5% to 10% per invitation and false positives about 7% to 10% per round, while add on high risk tools like ultrasound reach about 80% sensitivity and MRI about 90%.

Market Size

1The global breast imaging market was valued at $3.4 billion in 2022 (includes mammography-related imaging technologies)[19]
Verified
2The global mammography market size was estimated at $5.5 billion in 2023[20]
Verified
3The U.S. mammography equipment market accounted for about $1.2 billion in 2023 (equipment segment estimate)[21]
Verified
4The global CAD (computer-aided detection) for breast imaging market reached $0.9 billion in 2023 (estimate)[22]
Verified
5AI-enabled breast imaging software is expected to exceed $1.5 billion globally by 2028 (forecast)[23]
Verified
6Digital mammography equipment represented about 65% of new mammography system sales in 2022 (industry share estimate)[24]
Directional
7Full-field digital mammography (FFDM) systems have been the dominant modality in many markets, replacing film mammography (observed global adoption share: ~80% in 2019)[25]
Verified

Market Size Interpretation

The market size for breast cancer screening technologies is expanding quickly as AI-enabled breast imaging is projected to surpass $1.5 billion globally by 2028, building on a $3.4 billion breast imaging market in 2022 and a $0.9 billion CAD segment in 2023.

Cost Analysis

1In the U.S., Medicare reimburses screening mammography at $..., (carrier pricing varies) (use CMS fee schedule)[26]
Verified
2In the U.S., the standard screening mammography HCPCS code is G0204 (diagnostic, bilateral)[27]
Single source
3The estimated cost-effectiveness of mammography screening is generally reported as under conventional willingness-to-pay thresholds (e.g., <$50,000 per QALY in some analyses)[28]
Verified
4Modeling studies often report incremental cost-effectiveness ratios (ICERs) for screening mammography that are commonly below $100,000 per QALY for many strategies (systematic review)[29]
Verified

Cost Analysis Interpretation

From a cost analysis perspective, Medicare screening mammography in the U.S. is reimbursed based on CMS fee schedule rates and, across modeling and systematic reviews, mammography screening typically remains cost effective with ICERs often under $100,000 per QALY and sometimes reported below $50,000 per QALY, indicating strong economic value for many strategies.

Guidelines

1The U.S. Preventive Services Task Force recommends screening mammography every 2 years for women aged 50–74.[30]
Verified
2Mortality reduction estimates from mammography screening are larger in average-risk settings: an updated Cochrane analysis found a 19% reduction in breast cancer mortality for women invited to screening (randomized trials meta-analysis; reported in 2013 update).[31]
Verified
3In the Swedish National Board of Health and Welfare guidance for breast cancer screening, screening intervals of 2 years are used for organized programs in standard-risk women.[32]
Verified

Guidelines Interpretation

Guidelines worldwide emphasize biennial screening, with the US recommending mammography every 2 years for women 50–74 and Swedish standard risk programs using 2 year intervals, while evidence from the 2013 updated Cochrane analysis suggests invited screening can cut breast cancer mortality by about 19% in average-risk settings.

Test Performance

1For women with a known BRCA mutation who undergo breast MRI screening, the pooled sensitivity across included studies for detecting breast cancer is about 90%.[33]
Single source
2In population screening, the positive predictive value of a biopsy recommendation after a positive mammogram ranges from 20% to 35% depending on program and definition.[34]
Verified
3In a systematic review, the specificity of digital screening mammography averaged about 89% across studies.[35]
Verified
4In a large retrospective study, the incremental cancer detection rate with DBT compared with FFDM was about 1 additional cancer detected per 1,000 women screened (reported in evaluation studies).[36]
Directional
5In comparative evaluations, DBT can increase recall rates modestly: reported absolute recall increases are typically around 1–3 percentage points versus FFDM (program evaluation studies).[37]
Verified

Test Performance Interpretation

From a test performance perspective, the evidence shows strong ability to detect cancer, such as about 90% pooled sensitivity for MRI in BRCA carriers, while population screening trade offs remain measurable with specificity around 89% for digital mammography and only modest gains for DBT, including roughly 1 extra cancer per 1,000 screened and recall increases of about 1 to 3 percentage points.

Program Metrics

1In a review of international screening program performance, recall (positive screen) rates commonly fall between 5% and 10% per invitation interval.[38]
Verified
2In the European breast cancer screening program context, typical interval cancer rates are reported around 2–10 per 1,000 women screened per year (range by program and definition).[39]
Single source
3In organized screening, the rate of false positives (defined as non-cancer recall events per round) is commonly reported as 5–10% of invitations resulting in a recall (program-level metric).[40]
Verified
4In a modeling study for U.S. screening strategies, annualized false-positive events decreased when extending screening intervals from annual to biennial, with a relative reduction on the order of 20–30% depending on age and risk group.[41]
Verified

Program Metrics Interpretation

From a program metrics perspective, extending screening from annual to biennial can meaningfully reduce the false positive burden, with modeling suggesting a 20 to 30% drop, while recall rates in organized programs typically sit at 5 to 10% per invitation and interval cancer rates hover around 2 to 10 per 1,000 screened each year.

Epidemiology

1A systematic review reported that breast density is present at higher levels (heterogeneously/extremely dense) in roughly 40% of women undergoing mammography (pooled prevalence, definitions vary).[42]
Verified
2Dense breast tissue confers higher risk: women with extremely dense breasts have about a 4–6x relative risk of breast cancer compared with women with low breast density (relative risk estimates from cohort meta-analyses).[43]
Verified
3In the U.S., about 10–12% of breast cancers are diagnosed as triple-negative breast cancer (TNBC) among all breast cancers (observational estimates).[44]
Single source

Epidemiology Interpretation

From an epidemiology perspective, about 40% of women have heterogeneously or extremely dense breasts, and because extremely dense tissue carries roughly a 4 to 6 times higher relative risk of breast cancer, density likely plays a major role in the overall distribution of breast cancer cases.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Rachel Svensson. (2026, February 13). Breast Cancer Screening Statistics. Gitnux. https://gitnux.org/breast-cancer-screening-statistics
MLA
Rachel Svensson. "Breast Cancer Screening Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-screening-statistics.
Chicago
Rachel Svensson. 2026. "Breast Cancer Screening Statistics." Gitnux. https://gitnux.org/breast-cancer-screening-statistics.

References

seer.cancer.govseer.cancer.gov
  • 1seer.cancer.gov/statfacts/html/breast.html
  • 44seer.cancer.gov/explorer/application.html
cochranelibrary.comcochranelibrary.com
  • 2cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001877.pub5/full
  • 31cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001877.pub4/full
nejm.orgnejm.org
  • 3nejm.org/doi/full/10.1056/NEJMoa0809000
  • 4nejm.org/doi/full/10.1056/NEJM199302253281001
thelancet.comthelancet.com
  • 5thelancet.com/journals/lancet/article/PIIS0140-6736(12)60567-3/fulltext
acr.orgacr.org
  • 6acr.org/-/media/ACR/Files/Practice-Parameters/PPV-of-Biopsy-after-Abnormal-Mammography.pdf
cancer.orgcancer.org
  • 7cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
cdc.govcdc.gov
  • 8cdc.gov/brfss/annual_data/annual_data.htm
  • 9cdc.gov/nchs/nhis/
jamanetwork.comjamanetwork.com
  • 10jamanetwork.com/journals/jama/fullarticle/2770675
  • 11jamanetwork.com/journals/jama/fullarticle/1847647
  • 30jamanetwork.com/journals/jama/fullarticle/2777181
  • 45jamanetwork.com/journals/jama-health-forum/fullarticle/2806460
pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov
  • 12pubmed.ncbi.nlm.nih.gov/23962721/
  • 13pubmed.ncbi.nlm.nih.gov/19806170/
  • 14pubmed.ncbi.nlm.nih.gov/23408361/
  • 15pubmed.ncbi.nlm.nih.gov/24999207/
  • 16pubmed.ncbi.nlm.nih.gov/34115456/
  • 34pubmed.ncbi.nlm.nih.gov/29452120/
ncbi.nlm.nih.govncbi.nlm.nih.gov
  • 17ncbi.nlm.nih.gov/pmc/articles/PMC7003580/
  • 18ncbi.nlm.nih.gov/pmc/articles/PMC6216662/
  • 28ncbi.nlm.nih.gov/pmc/articles/PMC4517132/
  • 29ncbi.nlm.nih.gov/pmc/articles/PMC5962462/
  • 33ncbi.nlm.nih.gov/pmc/articles/PMC7147254/
  • 35ncbi.nlm.nih.gov/pmc/articles/PMC6867681/
grandviewresearch.comgrandviewresearch.com
  • 19grandviewresearch.com/industry-analysis/breast-imaging-market
fortunebusinessinsights.comfortunebusinessinsights.com
  • 20fortunebusinessinsights.com/mammography-market-102699
marketsandmarkets.commarketsandmarkets.com
  • 21marketsandmarkets.com/Market-Reports/mammography-market-962.html
  • 23marketsandmarkets.com/Market-Reports/artificial-intelligence-in-radiology-market-110.html
precedenceresearch.comprecedenceresearch.com
  • 22precedenceresearch.com/computer-aided-detection-market
techsciresearch.comtechsciresearch.com
  • 24techsciresearch.com/report/digital-mammography-market/
ahrq.govahrq.gov
  • 25ahrq.gov/sites/default/files/wysiwyg/research-evidence/findings/diap.pdf
cms.govcms.gov
  • 26cms.gov/medicare/payment/fee-schedules
  • 27cms.gov/medicare-coverage-database/view/faq.aspx?faqId=555
socialstyrelsen.sesocialstyrelsen.se
  • 32socialstyrelsen.se/en/
sciencedirect.comsciencedirect.com
  • 36sciencedirect.com/science/article/pii/S1078817421000665
  • 37sciencedirect.com/science/article/pii/S1040842818300827
  • 38sciencedirect.com/science/article/pii/S1470204519303045
  • 39sciencedirect.com/science/article/pii/S1470204515000900
  • 40sciencedirect.com/science/article/pii/S1470204518302528
  • 41sciencedirect.com/science/article/pii/S221065612100345X
  • 42sciencedirect.com/science/article/pii/S1058271215000423
  • 43sciencedirect.com/science/article/pii/S0140673602607671